Agenus | AGEN - Ebitda


Agenus reported $-10.11M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Celldex Therapeutics USD -83.58M 2.76M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 8.27B 1.08B Mar/2026
Jiangsu Hengrui CNY 2.56B 259.7M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck EUR 1.6B 69M Jun/2026
Merck USD -1.54B 7.84B Mar/2026
Northwest Biotherapeutics USD -13.41M 232K Sep/2023
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 6.01B 18M Jun/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 43.96M 1.16M Jun/2026